Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas

…, GF Tidmarsh, S Kroll, RL Wahl, SJ Knox… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: To evaluate the efficacy and safety of tositumomab and iodine I 131 tositumomab
(Bexxar; Corixa Corp, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA) in patients with …

[HTML][HTML] In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

…, RH Advani, YH Kim, RT Hoppe, SJ Knox… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Combining tumor antigens with an immunostimulant can induce the immune system
to specifically eliminate cancer cells. Generally, this combination is accomplished in an ex …

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

SJ Knox, ML Goris, K Trisler, R Negrin, T Davis… - Clinical cancer research …, 1996 - AACR
A Phase I/II dose escalation study of 90Y-murine anti-CD20 monoclonal antibody (mAb) in
patients with recurrent B-cell lymphoma was performed. The primary objectives of the study …

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

…, RL Wahl, M Saleh, AZ Rohatiner, SJ Knox… - Journal of clinical …, 2000 - ascopubs.org
PURPOSE: This multicenter phase II study evaluated the efficacy, dosimetry methodology,
and safety of iodine-131 tositumomab in patients with chemotherapy-relapsed/refractory low-…

A systemic complete response of metastatic melanoma to local radiation and immunotherapy

…, JC Jones, JA Mollick, SM Swetter, SJ Knox - Translational …, 2012 - Elsevier
BACKGROUND: Melanoma is a relatively immunogenic tumor, in which infiltration of melanoma
cells by T lymphocytes is associated with a better clinical prognosis. We hypothesized …

A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma

…, SM Swetter, S Saha, L Shura, SJ Knox - International Journal of …, 2016 - Elsevier
Purpose Local radiation therapy (RT) combined with systemic anti-cytotoxic T-lymphocyte–associated
protein-4 immunotherapy may enhance induction of systemic antimelanoma …

[PDF][PDF] Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed …

RI Fisher, MS Kaminski, RL Wahl, SJ Knox… - J Clin Oncol, 2005 - academia.edu
Purpose This study is an integrated efficacy analysis of the five clinical trials of tositumomab
and iodine-131 tositumomab in patients with relapsed or refractory low-grade, follicular, or …

Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma

…, S Lisby, O Baadsgaard, SJ Knox - Blood, The Journal …, 2007 - ashpublications.org
The efficacy and safety of zanolimumab in patients with refractory cutaneous T-cell
lymphoma (CTCL) have been assessed in two phase 2, multicenter, prospective, open-label, …

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer

SJ Knox, ML Goris, M Tempero, PL Weiden… - Clinical Cancer …, 2000 - AACR
A Phase II study of yttrium-90-tetra-azacyclododecanetetra-acetic acid-biotin ( 90 Y-DOTA-biotin)
pretargeted by NR-LU-10 antibody/streptavidin (SA) was performed. The primary …

[HTML][HTML] A review of newly diagnosed glioblastoma

…, TR Reid, A Oronsky, N Sandhu, SJ Knox - Frontiers in …, 2021 - frontiersin.org
Glioblastoma is an aggressive and inevitably recurrent primary intra-axial brain tumor with a
dismal prognosis. The current mainstay of treatment involves maximally safe surgical …